Wells Fargo’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $403K | Sell |
8,368
-46,025
| -85% | -$2.04M | ﹤0.01% | 4283 |
|
|
2025
Q4 | $2.24M | Buy |
54,393
+46,725
| +609% | +$1.87M | ﹤0.01% | 3340 |
|
|
2025
Q3 | $298K | Buy |
7,668
+2,551
| +50% | +$82.9K | ﹤0.01% | 4689 |
|
|
2025
Q2 | $142K | Sell |
5,117
-15,315
| -75% | -$390K | ﹤0.01% | 4977 |
|
|
2025
Q1 | $454K | Sell |
20,432
-670
| -3% | -$13.8K | ﹤0.01% | 4165 |
|
|
2024
Q4 | $417K | Buy |
21,102
+7,463
| +55% | +$170K | ﹤0.01% | 4314 |
|
|
2024
Q3 | $341K | Sell |
13,639
-494
| -3% | -$12K | ﹤0.01% | 4238 |
|
|
2024
Q2 | $264K | Buy |
14,133
+1,574
| +13% | +$29.5K | ﹤0.01% | 4328 |
|
|
2024
Q1 | $248K | Buy |
12,559
+1,964
| +19% | +$38.4K | ﹤0.01% | 4334 |
|
|
2023
Q4 | $186K | Sell |
10,595
-23,377
| -69% | -$384K | ﹤0.01% | 4504 |
|
|
2023
Q3 | $590K | Buy |
33,972
+1,019
| +3% | +$17.2K | ﹤0.01% | 3663 |
|
|
2023
Q2 | $464K | Buy |
32,953
+3,071
| +10% | +$41.1K | ﹤0.01% | 4002 |
|
|
2023
Q1 | $322K | Buy |
29,882
+28,988
| +3,243% | +$382K | ﹤0.01% | 4137 |
|
|
2022
Q4 | $13.4K | Sell |
894
-323
| -27% | -$4.7K | ﹤0.01% | 5431 |
|
|
2022
Q3 | $16K | Sell |
1,217
-315
| -21% | -$3.59K | ﹤0.01% | 5505 |
|
|
2022
Q2 | $15K | Sell |
1,532
-2,362
| -61% | -$22K | ﹤0.01% | 5586 |
|
|
2022
Q1 | $39K | Sell |
3,894
-10,229
| -72% | -$108K | ﹤0.01% | 5766 |
|
|
2021
Q4 | $166K | Sell |
14,123
-4,802
| -25% | -$59K | ﹤0.01% | 5369 |
|
|
2021
Q3 | $216K | Sell |
18,925
-13,711
| -42% | -$179K | ﹤0.01% | 5064 |
|
|
2021
Q2 | $455K | Sell |
32,636
-87,057
| -73% | -$1.32M | ﹤0.01% | 4670 |
|
|
2021
Q1 | $2.22M | Buy |
119,693
+47,478
| +66% | +$971K | ﹤0.01% | 3603 |
|
|
2020
Q4 | $1.28M | Buy |
72,215
+22,812
| +46% | +$401K | ﹤0.01% | 3838 |
|
|
2020
Q3 | $756K | Buy |
49,403
+9,217
| +23% | +$173K | ﹤0.01% | 4068 |
|
|
2020
Q2 | $1.02M | Buy |
40,186
+30,496
| +315% | +$637K | ﹤0.01% | 3798 |
|
|
2020
Q1 | $150K | Buy |
9,690
+1,862
| +24% | +$29.1K | ﹤0.01% | 4853 |
|
|
2019
Q4 | $86K | Buy |
7,828
+7
| +0.1% | +$61 | ﹤0.01% | 5350 |
|
|
2019
Q3 | $66K | Buy |
7,821
+513
| +7% | +$5.67K | ﹤0.01% | 5477 |
|
|
2019
Q2 | $99K | Sell |
7,308
-6,220
| -46% | -$96.5K | ﹤0.01% | 5316 |
|
|
2019
Q1 | $244K | Buy |
13,528
+3,787
| +39% | +$73.2K | ﹤0.01% | 4721 |
|
|
2018
Q4 | $273K | Buy |
9,741
+8,824
| +962% | +$184K | ﹤0.01% | 4726 |
|
|
2018
Q3 | $23K | Buy |
+917
| New | +$17.8K | ﹤0.01% | 5797 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
VPM
VCM
Wells Fargo's KNSA Position: Q1 2026 in Review
Wells Fargo reduced its Kiniksa Pharmaceuticals (KNSA) stake by 85% in Q1 2026, selling an estimated $2.04M and leaving 8,368 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #4283.
Wells Fargo first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.24M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.
- Wells Fargo held 8,368 shares of Kiniksa Pharmaceuticals worth $403K as of Q1 2026.
- Wells Fargo sold 46,025 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $2.04M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4283 holding.
- Wells Fargo first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
- Wells Fargo's Kiniksa Pharmaceuticals position peaked at $2.24M in Q4 2025.
- 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.